Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 302 participants.
Also called NCT06587347
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 302 participants
- Sponsor
- Registry
-
NCT06587347
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06587347. Randomized; single masking; primary purpose treatment. Start 2024-11-20 (anticipated); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke
- Acronym
- TREND-2
- Condition
- Acute Stroke
- Condition
- Ischemic Stroke, Acute
- Condition
- Cerebral Infarction
- Intervention (Drug)
- Tirofiban Hydrochloride
- Intervention (Drug)
- Standard medical treatment (SMT)
- Lead sponsor
- Capital Medical University
Record details
- Record id
cardio:ct-nct06587347- Content hash
c54eca1b30d0681e33498f6fb01727ca8223242f939a942b2ffdcb7e25ca2f6e